the LEO Pharma history timeline

Hormones are extracted from the urine of
pregnant women. The urine is collected
by LEO Pharma staff on pushbikes.
August Kongsted
LEO Pharma is
born in these
premises.
Anton Antons
The original LEO Pharma logo is sketched
in 1907 by artist Anna Rink, daughter of
the pharmacy owner at that time. She
was inspired by the Assyrian lions found
in Nebuchadnezzar’s palace in Babylon.
1908
The pharmacists Anton Antons and
August Kongsted found LEO Pharma
in 1908 when they receive royal
privilege from King Frederik VIII to run
the LEO Pharmacy in Copenhagen.
The original pharmacy receives royal
privilege in 1620
1909
A bacteriological and pharmacophysiological
laboratory opens at the LEO Pharmacy.
The production of sterile and standardised
preparations begins in these premises.
An inhalatorium for respiratory patients is
established
1914
Operations
1912
1910
in Sweden
Albyl® is
Three
employees marketed initiated
Albyl® is for
decades the most
popular painkiller
in Denmark.
LEO Pharma
finances the
development
and production
of insulin in the
1920s.
1926
80
employees
1917
In the newly established laboratories Dr. Marie
Krogh standardises digitalis, and the marketed drug
Digisolvin LEO® is the first Danish drug to be exported
1923
LEO Pharma enters
insulin production in
Denmark. In 1925,
insulin production is
transferred to the
independent
Nordisk
Insulinlaboratorium
Origin 1908-1929
1939-40
The son-in-law of Kongsted, Knud
Abildgaard takes the reins of LEO Pharma.
200+ employees.
The LEO Pharma price list contains
approx. 230 branded products
1945
Penicillin LEO® is marketed.
LEO Pharma is the first company
outside of the UK and the US to
manufacture penicillin
1926
80 employees
1930
LEO Pharma develops
a number of hormone
products
1958
2500
employees
Bottles are filled.
Knud Abildgaard
1901-1986
Waiting room in
the inhalatorium
situated on top of
the LEO Pharmacy.
Early 20th century.
1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928
1908
August Kongsted
1870-1939
Dr. Marie Krogh.
Penicillin, the new
life-saving drug,
is considered a
medical miracle.
Abildgaard
establishes
LEO Phama as
the first penicillinproducing
company outside
of the UK and the
US.
1936
Heparin
extraction
method
is developed
1940
Heparin LEO® is marketed
1946-48
The first bricks are laid in Ballerup,
Denmark for LEO Pharma’s new
headquarters.
Penicillin production plants are built under
license in Italy, Spain and France
1949
From 1949 to 1959, LEO Pharma moves
all production to the new headquarters in
Ballerup, Denmark and begins exporting
pharmaceutical products
1951
Protaminsulphat LEO is marketed
The current
LEO Pharma logo
is registered as the
official trademark
in 1956.
In 1973, a nephrologist asked LEO to
develop D vitamins for his renal patients.
Five years later, One-Alpha® is launched.
In 1958, at the
50th anniversary
of the company,
Abildgaard is
given a lion cub.
The lion is donated
to the Copenhagen
Zoo.
Fusidic acid, a completely new antibiotic
substance derived from the fungus
Fusidium coccineum, was discovered by
LEO Pharma researchers in 1959.
Few years later, Fucidin® was launced.
1958
Rontyl® is marketed.
Operations in France, Holland, Ireland and
Greece initiated
1960
Centyl® is marketed.
Operations in the UK initiated.
New operations in Sweden initiated
1962
Fucidin® is developed
and marketed.
Operations in
Norway initiated
1971
The next new
generation of
penicillins,
1970 Pondocillin®,
Knud Abildgaard is marketed
publicly announces a
possible Foundation
ownership
1967
Kaleorid® is
marketed
1973
Burinex® is marketed.
LEO Pharma research into
vitamin D analogues begins
1976
Heparin plant in
Esbjerg,
Denmark
established
1984
The LEO Foundation
established
1977
Operations in
Belgium initiated
1983
Operations in
Canada initiated
1978
One-Alpha® and Selexid®
are marketed
1979
Operations in
Middel East initiated
1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 19431944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984
1929
Biotech 1930-1984
LEO Pharma
develops the
vitamin D product,
Daivonex®
(calcipotriol) for
the treatment of
psoriasis.
In 1994, Daivonex®
is awarded the
Belgian prestigious
pharmaceutical
award Prix Galien.
1990
Operations in
Finland initiated
1986
Knud Abildgaard
passes away.
LEO Pharma is from
now on 100 %
owned by the
1988
LEO Foundation.
Operations
®
Fucidin H is
in Poland
marketed
initiated.
1987
Operations
®
Fucicort
in Asia
is
initiated
marketed
Stability
H
O
OH
H
F
The D vitamin
analogue,
calcipotriol, is
synthesized in
1985.
Operations in Switzerland initiated
OH
OH
HO
In 2000, LEO Pharma
is awarded King
Frederik IX’s Award
for Excellence in
Export.
1992
Operations in Germany initiated
1994
3,000 employees
world-wide
including 1,250
at headquarters
in Ballerup,
1995
Denmark
Operations in
Spain initiated
1996
Operations
in Austria
initiated
1997
Operations
in Portugal
initiated
1998
An R&D complex with
state-of-the-art facilities
is built in Ballerup
The Product Award
2003 from the
Confederation of
Danish Industries
goes to Daivobet®/
Dovobet®.
Calcipotriol
H
H
0
7
14
pH
In 2001, LEO Pharma manages to
combine two unmixable compounds:
calcipotriol and betamethasone
dipropionate, and Daivobet®/Dovobet®/
Taclonex® is a reality.
2003
Daivobet®/Dovobet®
receives the Product
Award 2003 from the
Confederation of Danish
Industries.
Global 1985-2008
We help people
achieve healthy skin
In 2008,
LEO Pharma
celebrates its 100
years anniversary.
2008
Taclonex Scalp® Topical
Suspension approved in the US.
Xamiol® is launched
2000
LEO is awarded an
environmental award Operations in Tunisie
Københavns Amt Miljøpris.
initiated
LEO Pharma is awarded
King Frederik IX’s Award for
2005
Excellence in Export
Daivobet®/Dovobet® is
approved
to be launched
2001
in the US under the name
Daivobet®/
Taclonex®
Dovobet®
2009
LEO Pharma acquires Australian/American
biotech company Peplin, Inc.
LEO Pharma establishes a legal entity in China.
Operations in Australia and the US initiated
In 2013,
LEO Pharma
reinforces its new
mission statement
through a new
corporate identity.
2013
4800
employees
2011
LEO Pharma introduces its new mission:
We help people achieve healthy skin.
Operations in Italy, Turkey and South Korea initiated
2010
2012
Operations
Picato® is launched in the US
in Brazil,
Japan and
2013
Mexico
Picato® is launched in the European Union
initiated
is marketed 2002
Operations LEO Pharma changes the Danish
in Morocco company name Løvens kemiske
Fabrik to the more international
initiated
name LEO Pharma.
Operations in Algeria initiated
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
1985
— we help people
achieve healthy skin
OH
HO
O
innohep® syringes
in safety packaging.
1991
Daivonex®/Dovonex®
and innohep® are launched.
Betamethasone
dipropionate
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
LEO and the LEO Lion Design are registered trademarks of LEO Pharma A/S.
©2012 LEO Pharma Inc.
Hanne Simone Grafisk Design All rights reserved. 03/2013
2009
From 2009 and onwards
LEO Pharma A/S
Industriparken 55
DK — 2750 Ballerup
Phone
+45 4494 5888
Fax
+45 7226 3323
www.leo-pharma.com
LEO Pharma
Timeline
From origin to biotech to global and onwards
1908-2013